Brief: Heidelberg Pharma Wins U.S. Patent Rights For TP53/RNA Polymerase II Deletion Treatment
04/03/2020 06:20
March 4 (Reuters) - HEIDELBERG PHARMA AG WL6G.DE :
* US PATENT RIGHTS GRANTED FOR DIAGNOSIS AND TREATMENT OF
PATIENTS
WITH TP53/RNA POLYMERASE II DELETION
* HEIDELBERG PHARMA AG - HEIDELBERG PHARMA HOLDS AN
EXCLUSIVE
LICENSE TO THESE PATENT RIGHTS
Source text for Eikon: ID:nEQDpW2La
Further company coverage: WL6G.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Heidelberg Pharma AG
See all newsBrief: Heidelberg Pharma And Huadong Medicine Receive Nmpa Approval For Hdp-101 Trial In China
Germany's Heidelberg Pharma H1 sales revenue surges, driven by milestone payments
Brief: Heidelberg Pharma Says Co. And Healthcare Royalty Announce Amendment To Existing Royalty Agreement
Brief: Redhill Biopharma Secures Allowance Of Key Chinese Patent Application For Proprietary COVID-19 Treatment, RHB-107
Brief: Heidelberg Pharma Amends Royalty Financing With Healthcare Royalty